A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

This early-phase study tests a new drug called HDM2005 in people with relapsed or refractory B-cell lymphoma (a blood cancer) or advanced solid tumors that have not responded to standard treatments. The study first evaluates safety and dosing, then expands to look at effectiveness. **You may be eligible if...** - You are 18 years old or older - You have been diagnosed with B-cell lymphoma (ECOG 0–2) or advanced solid tumors (ECOG 0–1) that have relapsed or progressed after standard treatments - Your expected survival is at least 3 months - You have adequate organ function and blood counts **You may NOT be eligible if...** - You have had recent stem cell transplantation or CAR-T therapy - You have active brain metastases that are untreated - You have serious autoimmune conditions or are on immune-suppressing drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.